Navigation Links
Dendreon Announces Pricing of $540 Million Convertible Senior Notes Due 2016
Date:1/14/2011

net proceeds of the offering of the Notes to fund the continued investment in and expansion of its manufacturing facilities, including the construction of a new immunotherapy manufacturing facility in Europe and the expenses associated with increasing capacity at its existing Morris Plains, New Jersey, Atlanta, Georgia and Orange County, California facilities; cover expenses in connection with pursuing non-U.S. marketing approvals for PROVENGE® (sipuleucel-T); fund new clinical trials for PROVENGE and other product candidates; finance its marketing and awareness efforts for PROVENGE; fund the ongoing hiring of additional manufacturing, sales and marketing, quality, research and development and other personnel to support PROVENGE and its other product candidates; fund additional investment in information technology infrastructure and product support systems; for third-party contract supply costs; and for general corporate purposes, including working capital.  Dendreon may also use a portion of the net proceeds to acquire strategic assets, although Dendreon currently has no agreements or commitments to do so.

In connection with the offering of the Notes, the underwriter expects to distribute in an offering registered under the Securities Act 1,787,100 outstanding shares of Common Stock (subject to minor adjustments related to the allocation of the Notes) to facilitate the hedging of the Notes by buyers of the Notes.  Dendreon has been advised by the underwriter that it purchased the shares of Common Stock from buyers of the Notes in connection with, and contingent on the closing of, the Notes offering, with a view to initially offer the shares of Common Stock to the public at a price of $35.70 per share and to subsequently offer the shares of Common Stock in one or more transactions on The NASDAQ Global Select Market, in the over-the-counter market, through negotiated transactions or otherwise at the market prices prevailing at the time of the s
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 /PRNewswire-iReach/ -- A case ... collaboration between the school,s bioengineering department and the ... the Intel® Software Academic Program, UCSD,s research focuses ... the human body.  Photo - ... exhibits the work of Dr. Todd P. ...
(Date:8/19/2014)... 2014 Shimadzu Scientific Instruments has ... and Nexera-i, adding to the company’s extensive line-up ... an intuitive operating environment, and full automation, the ... workflow for conventional to ultra-high-speed analysis. ... intelligent design so users can begin building the ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 Robin Williams’ ... disease can take on an individual. Symptoms range ... facial expression, problems swallowing and severe depression. Parkinson’s ... dying off of dopamine producing neurons of the brain. ... a disease that slowly and progressively gets worse, they ...
(Date:8/19/2014)... , Aug. 19, 2014   Synthetic ... company developing novel anti-infective biologic and drug programs ... diseases, announced today that its novel C. ... the 54 th Interscience Conference on Antimicrobial ... Washington D.C. Synthetic ...
Breaking Biology Technology:Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4
... YORK, March 21, 2011 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, ... "AOBO"), a pharmaceutical company dedicated to improving health through ... of prescription and over the counter ("OTC") products, announced ... 15, 2010, that its board of directors authorized a ...
... Md., March 21, 2011 United Therapeutics Corporation ... enrollment in its FREEDOM-C(2) registration trial was completed ... a 16-week, multi-center, international, double-blind, randomized, placebo-controlled study ... diethanolamine (UT-15C) in pulmonary arterial hypertension (PAH) patients ...
... Recent events in Japan have caused the world to ... be a cause for concern – especially if radiation ... proliferating cells of the body. Cells of the hematopoietic ... two such cell types. Damage to these cells initiates ...
Cached Biology Technology:American Oriental Bioengineering Announces US$20 Million Share Repurchase Program 2United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial 2Existing Radiation Countermeasures Inadequate! Development of Rx100 Promises Change! 2Existing Radiation Countermeasures Inadequate! Development of Rx100 Promises Change! 3
(Date:8/20/2014)... Aug. 20, 2014 George E. Fox, a John and ... of Houston (UH), was named a fellow in the International ... , Fox is one of four members two ... chosen as fellows in 2014. Fellows are elected every ... more than 500 members from more than 20 countries, the ...
(Date:8/20/2014)... of 158 pregnant teenagers in Rochester, NY, nearly half ... of ice, cornstarch, vacuum dust, baby powder and soap, ... , Moreover, such teens had significantly lower iron levels ... substances. , Pregnant teens, regardless of pica, are at ... iron deficiency and anemia. Low iron in pregnant teens ...
(Date:8/20/2014)... Researchers at Huntsman Cancer Institute (HCI) at the University ... the gene that encodes BCR-ABL, the unregulated enzyme driving ... the American Cancer Society, nearly 6,000 new cases of ... in use, called tyrosine kinase inhibitors (TKIs), target BCR-ABL ... not cure CML but control it in a way ...
Breaking Biology News(10 mins):UH professor named fellow by International Astrobiology Society 2Pica in pregnant teens linked to low iron 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... Even healthy pregnant women can be at risk for ... Reserve University began to understand which bacteria from the 700 ... health problem of preterm and stillbirths. Yiping Han ... Dental Medicine led the study, which found several new bacteria ...
... laboratories, two Dartmouth biologists have performed one of the largest ... population. Their results, published online on May 9 by the ... more important than predation by birds and snakes when it ... Tennyson wrote that nature is ,red in tooth and claw, ...
... May 7, 2010 In findings that advance scientists, ... from The Scripps Research Institute has shed light on a ... other lysosomal storage diseases. The findings were published in ... Biology on May 9, 2010. "This study is ...
Cached Biology News:Even healthy pregnant women need to worry about oral bacteria 2Researchers use entire islands in the Bahamas to test survival of the fittest 2Scripps research scientists shed light on potential treatment for Gaucher's disease 2Scripps research scientists shed light on potential treatment for Gaucher's disease 3Scripps research scientists shed light on potential treatment for Gaucher's disease 4
... The Yeast Whole Genome ChIP-on-chip Microarray ... of yeast (S. cerevisiae) DNA binding ... with Agilent DNA microarrays. This set ... data with greater true binding events ...
... DTT White solid. ... Purity: ≥99% by titration. ... Absorbance: (100 mM, 280 nm):≤0.05. ... or H 2 O. RTECS ...
... pombe Whole Genome ChIP-on-chip Microarray is ... yeast (S. pombe) DNA binding proteins ... Agilent DNA microarrays. This set delivers ... with greater true binding events and ...
... The recent sequencing of Salmonella genomes ... enterica Typhimurium ORFmer PCR* primer pairs. The ... of a single chromosome (4,857,432 bp; 4,440 ... 107 ORFs). These ORFmers from Sigma-Genosys have ...
Biology Products: